These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22506768)

  • 21. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
    Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.
    Esteban E; Majem M; Martinez Aguillo M; Martinez Banaclocha N; Dómine M; Gómez Aldaravi L; Juan O; Cajal R; Gonzalez Arenas MC; Provencio M
    Cancer Epidemiol; 2015 Jun; 39(3):291-7. PubMed ID: 25766256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
    Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
    Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
    Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
    Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
    Yu J; Kane S; Wu J; Benedettini E; Li D; Reeves C; Innocenti G; Wetzel R; Crosby K; Becker A; Ferrante M; Cheung WC; Hong X; Chirieac LR; Sholl LM; Haack H; Smith BL; Polakiewicz RD; Tan Y; Gu TL; Loda M; Zhou X; Comb MJ
    Clin Cancer Res; 2009 May; 15(9):3023-8. PubMed ID: 19366827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.
    Giannini R; Lupi C; Sensi E; Alì G; Proietti A; Boldrini L; Servadio A; Giordano M; Macerola E; Bruno R; Borrelli N; Chella A; Melfi F; Lucchi M; Ribechini A; Vasile E; Cappuzzo F; Mussi A; Fontanini G
    Oncol Rep; 2016 Aug; 36(2):1166-72. PubMed ID: 27373829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.
    Cadranel J; Zalcman G; Sequist L
    Eur Respir J; 2011 Jan; 37(1):183-93. PubMed ID: 21030453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
    Esterbrook G; Anathhanam S; Plant PK
    Lung Cancer; 2013 Apr; 80(1):30-4. PubMed ID: 23312886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of multiple gene mutations in non-small-cell lung cancer by suspension microarray].
    Wang D; Ye YK; Su CQ; Rong TH; Guo AY; Yi JH; Liu YJ
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(48):3393-6. PubMed ID: 20223111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
    Bergot E; Levallet G; Creveuil C; Lechapt E; Zalcman G
    Presse Med; 2011 Apr; 40(4 Pt 1):379-88. PubMed ID: 21376511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
    Berg J; Fjellbirkeland L; Suhrke P; Jebsen P; Lund-Iversen M; Kleinberg L; Helgeland L; Brustugun OT; Helland Å
    Acta Oncol; 2016; 55(2):149-55. PubMed ID: 26313507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 38. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort.
    Kaanane H; El Attar H; Louahabi A; ; Berradi H; Idrissi HH; Khyatti M; Nadifi S
    Gene; 2019 Jul; 705():36-43. PubMed ID: 31004715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia.
    Gervas P; Ivanova A; Vasiliev N; Ananina O; Zharkova O; Rogovieva O; Verzhbitskaya N; Didichuk I; Cheremisina O; Popova N; Goldberg V; Cherdyntsev E; Choynzonov E; Cherdyntseva N
    Asian Pac J Cancer Prev; 2015; 16(2):689-92. PubMed ID: 25684509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.